DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG
发明人:
CLEMENT BERND,클레멘트, 베른트,KOTTHAUS JURKE,토크하우스, 유어케,KOTTHAUS JOSCHA,토크하우스, 요슈아,SCHADE DENNIS,샤데, 데니스
申请号：
KR1020147004769
公开号：
KR1020140049021A
申请日:
2012.07.05
申请国别(地区):
KR
年份:
2014
代理人:
摘要：
Substituted dabigatran compounds (I) are new. Substituted dabigatran compounds of formula (I) and their derivatives, salts, solvates, or the solvates of salts are new. R1 : H or optionally branched, optionally saturated and optionally substituted 1-12C-hydrocarbon chain and n : 1-10. Independent claims are included for: (1) a drug comprising (I) in combination with one or more further active agents and (2) the preparation of (I). [Image] ACTIVITY : Hemostatic Thrombolytic Cerebroprotective Vasotropic Cardiant Antiarrhythmic Cytostatic. MECHANISM OF ACTION : Serine protease inhibitor.본 발명은 다비가트란의 전구약물 유도체, 질병, 특히, 혈전성 질환, 뇌졸중, 심근 경색 및/또는 심방 세동과 심부정맥은 물론 임의 병리적 종양적 질환의 치료 및/예방에의 용도에 관한 것이다.
